Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations
08:00am, Tuesday, 15'th Dec 2020
Former head of commercial API manufacturing at Gilead Sciences will lead technical operations for development of Cidara's antifungal and antiviral programs Former head of commercial API manufacturing
Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference
08:00am, Tuesday, 01'st Dec 2020
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patien
Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020
08:00am, Monday, 30'th Nov 2020
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patien
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
04:05pm, Wednesday, 11'th Nov 2020
SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patien
Cidara Therapeutics (CDTX) Reports Q3 Loss, Misses Revenue Estimates
09:00pm, Thursday, 05'th Nov 2020
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 14.58% and -32.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stoc
Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial Results
04:24pm, Thursday, 05'th Nov 2020
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patien
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
10:05pm, Thursday, 13'th Aug 2020
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -87.50% and -79.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Cidara Provides Corporate Update and Reports Second Quarter 2020 Financial Results
08:48pm, Thursday, 13'th Aug 2020
SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing
Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
12:00pm, Tuesday, 04'th Aug 2020
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing
Cidara Therapeutics Announces Formation of Scientific Advisory Board
12:00pm, Monday, 27'th Jul 2020
Comprised of World-Renowned Experts in Virology, Fungal Diseases and HematologySAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing
What Is The Ownership Structure Like For Cidara Therapeutics, Inc. (NASDAQ:CDTX)?
02:02pm, Sunday, 19'th Jul 2020
Every investor in Cidara Therapeutics, Inc. (NASDAQ:CDTX) should be aware of the most powerful shareholder groups...
Cidara Therapeutics to Participate in B. Riley Virtual Summer Series Panel on Antiviral Therapeutics
12:00pm, Friday, 17'th Jul 2020
SAN DIEGO, July 17, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients.
Here is What Hedge Funds Think About Cidara Therapeutics Inc (CDTX)
02:02am, Monday, 06'th Jul 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Cidara Therapeutics Added to Russell 3000® Index
12:00pm, Monday, 29'th Jun 2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced
Cidara Therapeutics Inc (NASDAQ:CDTX) Given Consensus Rating of “Buy” by Brokerages
02:02am, Wednesday, 24'th Jun 2020
Shares of Cidara Therapeutics Inc (NASDAQ:CDTX) have been assigned an average rating of “Buy” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One investment a
